Hazardous Drug Sampling
EOC1 can provide hazardous drug testing for marker drugs in your facility to meet guidelines set forth by NIOSH, OSHA and USP <800>. EOC1 was one of the first companies providing antineoplastic environmental monitoring for our customers compounding chemotherapy drugs. We helped develop the original sampling process and analytics used by many companies today. Although analytical methods are not available for all hazardous drugs we are capable of handling many chemo and hormonal drugs.
With the promulgation of USP <800>, compounding of hazardous drugs are coming under more scrutiny by inspectors. Early work was performed originally in the 1990s by the American Society of Hospital Pharmacists (now known as the American Society of Health-System Pharmacists ) to define threats by hazardous drugs that include categories such chemotherapy, hormones and antiviral drugs as well as others. NIOSH lists these drugs in three groupings*:
Antineoplastic drugs (AHFS Classification 10:00) [ASHP/AHFS DI 2013]. Note that many of these drugs may also pose a reproductive risk for susceptible populations.
Non-antineoplastic drugs that meet one or more of the NIOSH criteria for a hazardous drug. Note that some of these drugs may also pose a reproductive risk for susceptible populations.
Drugs that primarily pose a reproductive risk to men and women who are actively trying to conceive and women who are pregnant or breast feeding, because some of these drugs may be present in breast milk.
USP <800> states:
“Environmental wipe sampling for HD surface residue should be performed routinely (e.g., initially as a benchmark and at least every 6 months, or more often as needed, to verify containment). “:
“If any measurable contamination is found, the designated person must identify, document, and con-tain the cause of contamination. Such action may include reevaluating work practices, re-training personnel, performing thor-ough deactivation, decontamination, cleaning, and improving engineering controls. Repeat the wipe sampling to validate that the deactivation/decontamination and cleaning steps have been effective. “
*Citation: NIOSH . NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2014. By Connor TH, MacKenzie BA, DeBord DG, Trout DB, O’Callaghan JP.. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2014-138 (Supersedes 2012-150). DHHS (NIOSH) Publication Number 2014-138 (Supersedes 2012-150). September 2014